| scholarly article | Q13442814 |
| P50 | author | Julie A Lynch | Q87317715 |
| P2093 | author name string | Brygida Berse | |
| Atreya Dash | |||
| Jeffrey Lawrence | |||
| Laurence Meyer | |||
| Will Lowrance | |||
| Michael Brawer | |||
| Deborah Hartzfeld | |||
| P2860 | cites work | The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy | Q24596735 |
| Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer | Q27852185 | ||
| Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study | Q33927384 | ||
| Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular | Q34159011 | ||
| Guideline for the management of clinically localized prostate cancer: 2007 update. | Q34629234 | ||
| BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients | Q35527158 | ||
| Germline BRCA1 mutations increase prostate cancer risk | Q35949522 | ||
| Cancer risks among BRCA1 and BRCA2 mutation carriers | Q36610578 | ||
| Germline BRCA mutations denote a clinicopathologic subset of prostate cancer | Q37019841 | ||
| The role of BRCA1 and BRCA2 in prostate cancer | Q37037789 | ||
| A critical review of clinical practice guidelines for the management of clinically localized prostate cancer | Q37190040 | ||
| Clinical features and management of BRCA1 and BRCA2-associated prostate cancer | Q38175688 | ||
| Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/In | Q38259724 | ||
| Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer | Q38592417 | ||
| A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. | Q46658469 | ||
| Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. | Q52838313 | ||
| Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. | Q55067996 | ||
| Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers | Q58143504 | ||
| Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy | Q80744531 | ||
| Predictive models for newly diagnosed prostate cancer patients | Q84912363 | ||
| Clinical Management of Prostate Cancer in Men with BRCA Mutations | Q86168061 | ||
| P433 | issue | Suppl 1 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 46S-51S | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | Federal practitioner : for the health care professionals of the VA, DoD, and PHS | Q27723489 |
| P1476 | title | Caring for Patients With Prostate Cancer Who Are BRCA Positive | |
| P478 | volume | 33 |
Search more.